I would like to understand the process rather than be told to try harder.
I want to know whether this is a real physical effect or an artefact of how it is measured.
What prompted the question is an inconsistency between two sources I otherwise trust.
Is the standard explanation correct, and if so, what is the evidence for it?
Answering this needs the jurisdiction, since the framework differs substantially between countries and even between states.
A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.
Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.
Beyond-use dating for compounded sterile preparations is governed by published standards keyed to the compounding environment.
Ask which salt form. A different salt is a different active moiety.
edited 12 Jun 2026 by Dr_Tomas_Kral — updated for the 2026 guidance change
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe underlying point is that copies of commercially available products are generally not permitted, which is the constraint that shapes most of this market.
Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.
The part that matters: beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.
Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.
Compounded means unapproved by definition. That is structural, not pejorative.
Start with the regulatory basis, because compounding is permitted under specific conditions and those conditions are the whole subject.
Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.
Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.
A compounded preparation is unapproved by definition, which is a statement about the framework rather than about the facility.
Ask for the certificate of analysis on the lot. A serious facility has one.
This is an area where the legal position and the quality question are separate and both matter.
Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.
Facility quality is the dominant variable and cannot be assessed from a website.
Check the beyond-use date and what it was based on.
Answer first: a compounded preparation is made for an individual under a prescription and is not an approved product, so it carries neither the release testing nor the pharmacovigilance of one.
Additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.
Nothing here is medical advice.
The framework is jurisdiction-specific. Check yours rather than a general answer.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.